Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus R Herrlinger

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Inflammatory Bowel Diseases|August 5, 2004
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitisKlaus R Herrlinger, Rike Dittmann, Gunther Weitz, et al.
Therapeutic Drug Monitoring|March 11, 2010
Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?Susanne Karner, Shaojun Shi, Christine Fischer, et al.
Emerging Infectious Diseases|March 23, 2021
Tula Virus as Causative Agent of Hantavirus Disease in Immunocompetent Person, GermanyJörg Hofmann, Stephanie Kramer, Klaus R Herrlinger, et al.
Inflammatory Bowel Diseases|August 7, 2003
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitisJan Wehkamp, Juergen Harder, Michael Weichenthal, et al.
Pharmacogenetics and Genomics|September 6, 2005
The pharmacogenetics of methotrexate in inflammatory bowel diseaseKlaus R Herrlinger, J R Fraser Cummings, Martin C N M Barnardo, et al.
European Journal of Gastroenterology & Hepatology|August 10, 2002
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel diseaseJan Wehkamp, Klaus Fellermann, Klaus R Herrlinger, et al.
The American Journal of Gastroenterology|April 26, 2006
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's diseaseKlaus R Herrlinger, Thomas Witthoeft, Andreas Raedler, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Journal of Clinical Medicine|September 10, 2021
Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients-Results from the CORONA Germany StudyMelanie A Gunawardene, Nele Gessler, Peter Wohlmuth, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Inflammatory Bowel Diseases|August 5, 2004
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitisKlaus R Herrlinger, Rike Dittmann, Gunther Weitz, et al.
Therapeutic Drug Monitoring|March 11, 2010
Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?Susanne Karner, Shaojun Shi, Christine Fischer, et al.
Emerging Infectious Diseases|March 23, 2021
Tula Virus as Causative Agent of Hantavirus Disease in Immunocompetent Person, GermanyJörg Hofmann, Stephanie Kramer, Klaus R Herrlinger, et al.
Inflammatory Bowel Diseases|August 7, 2003
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitisJan Wehkamp, Juergen Harder, Michael Weichenthal, et al.
Pharmacogenetics and Genomics|September 6, 2005
The pharmacogenetics of methotrexate in inflammatory bowel diseaseKlaus R Herrlinger, J R Fraser Cummings, Martin C N M Barnardo, et al.
European Journal of Gastroenterology & Hepatology|August 10, 2002
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel diseaseJan Wehkamp, Klaus Fellermann, Klaus R Herrlinger, et al.
The American Journal of Gastroenterology|April 26, 2006
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's diseaseKlaus R Herrlinger, Thomas Witthoeft, Andreas Raedler, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Journal of Clinical Medicine|September 10, 2021
Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients-Results from the CORONA Germany StudyMelanie A Gunawardene, Nele Gessler, Peter Wohlmuth, et al.
Pageof 4